The approval comes after positive results from the LIBERTY 1 and 2 studies were published, which showed safety and efficacy of the medication after 24 weeks.
The approval comes after results from 2 phase 3 trials showed that the medication significantly reduced the amount of heavy bleeding compared with placebo.
